Management of Hepatitis with Indigenous drugs

A Clinical study on Yakrit vikara w.s.r to Hepatitis and its management with Indigenous drugs - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067339

Enrollment

Registered

2024-05-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K701- Alcoholic hepatitis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Drug induced hepatitis Hepatitis A & E Alcohol induced hepatitis

Exclusion criteria

Exclusion criteria: Hepatitis with other metabolic disorders Lactating & pregnant women auto-immune hepatitis Hepatitis B,C,D

Design outcomes

Primary

Measure	Time frame
To get the billirubin quantity to normal levels and to cure the echogenesity of liver parenchymal cellsTimepoint: 3 months	—

Secondary

Measure	Time frame
To reduce the elevated liver enzymes and viral loadTimepoint: 3 months	—

Countries

India

Contacts

Public ContactProf Dr Pragya Priyadarsini Mallik

Gopabandhu Ayurveda Mahavidyalaya

pragya2506@gmail.com9437212898

Outcome results